A new clinical trial option is now available for dogs with melanoma, osteosarcoma, soft tissue sarcoma or squamous cell carcinoma.

Trial Summary
A minimum of 100 dogs with solid tumors will be treated with modified anaerobic bacteria. Treated dogs will be monitored closely after treatment with follow-up required at 2,4,7, and 14 days. While the patient remains on study, there will also be rechecks at 1 and 2 months from the initial treatment.

Trial Support and Funding
Study drug, diagnostic tests, and follow-up exams will be paid for by the study sponsor. In the event that side effects are attributed to the study drug, the study will pay for medical management of the side effects.

Trial Eligibility
Inclusion Criteria Includes:

• Client-owned dogs with solid tumors with a preference for squamous cell carcinoma and sarcomas
• Histologic or cytologic confirmation of tumor diagnosis
• Dogs that have failed standard therapy or whose owners have declined such therapy
• At least one palpable lesion measuring ≥ 1 cm in diameter
• Dogs able to function normally (Modified ECOG Performance Score of 0 or 1)

Exclusion Criteria Includes:

• Evidence of an active bacterial infection based on physical examination and/or complete blood count evaluation
• Received antibiotic therapy within 7 days prior to infusion for a confirmed or suspected infection
• Cancer therapy of any type (chemotherapy, radiation therapy, immunotherapy, etc.) within 3 weeks of study treatment
• Tumors located in areas where abscess development would be catastrophic, such as nasal tumors that extend into the brain or significant pulmonary metastatic disease